Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,otherCurrentAssets,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,preMarketChange,preMarketChangePercent,preMarketTime,preMarketPrice,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,priceHint,shortName,longName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,market,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,exchangeDataDelayedBy,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2021) 4","Short Ratio (Jul 14, 2021) 4","Short % of Float (Jul 14, 2021) 4","Short % of Shares Outstanding (Jul 14, 2021) 4","Shares Short (prior month Jun 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,JAGX,7975000.0,137318000,2414000,,-12009000,,-12009000,5548000,658000,-7304000,-7304000,,-1901000,,,,0,1241000,8545000,583000,-4705000,,-12009000,-12009000,23916000.0,210786000.0,36822000.0,31891000.0,12000.0,68713000.0,13000.0,-178908000.0,19000.0,32250000.0,12592000.0,1431000.0,674000.0,44104000.0,5927000.0,24230000.0,2821000.0,4740000.0,,-113000,9058000,30868000,1692000,23685000,24160000,-6708000,431000,-39000,-1365000,-1875000,3497000,31512000.0,en-US,US,EQUITY,True,Delayed Quote,USD,0.83333254,1.19 - 1.23,1.2,0.0,0.0,361,280,finmb_12827020,NasdaqCM,USD,6713939,2428228,1.0250001,5.540541,0.185 - 4.47,-3.2599998,-0.72930646,0.185,4.47,1559865600,1621249140,1628679540,1629115200,0.00999999,0.82644546,1630575073,1.22,-0.638,-0.2,-0.26,-4.6538463,-14400000,0.249,1.3308572,-0.12085712,-0.09081149,1.655,-0.44499993,4,"Jaguar Health, Inc.","Jaguar Health, Inc.",1.21,1630526403,0.00999999,1.2,1.23,1.19,2099627,PRE,NCM,us_market,-0.26888213,166157200,-6.05,4.859438,15,America/New_York,EDT,False,False,0,1.35,,,4.47,0.185,1.3309,1.655,6.71M,2.43M,137.32M,,136.09M,5.15%,11.50%,8.44M,1.38,6.15%,6.15%,8.06M,,,,,,0.00%,"Jun 06, 2019",,1:70,"Jun 06, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,-232.84%,-27.84%,-156.22%,9.76M,0.15,42.80%,6.11M,-20.99M,-42.24M,-0.6380,,32.25M,0.23,25.66M,80.46,3.50,0.25,-17.69M,-11.36M,Value,94104,Healthcare,34,"Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.",San Francisco,415 371 8300,CA,1609372800,United States,http://www.jaguar.health,86400,200 Pine Street,Biotechnology,Suite 400
t-1,JAGX,-7135000.0,137318000,1904000,,-8769000,,-8769000,5050000,1787000,-5167000,-5167000,,-1533000,,,,0,2576000,7743000,789000,-3602000,,-8769000,-11364000,24337000.0,184090000.0,25641000.0,17202000.0,179000.0,42843000.0,11000.0,-166899000.0,37000.0,8090000.0,13220000.0,3789000.0,677000.0,17792000.0,2126000.0,12421000.0,2782000.0,4759000.0,2434000.0,-747000,14077000,10802000,-2402000,903000,6741000,-4061000,431000,-563000,123000,-4178000,5889000,4572000.0,en-US,US,EQUITY,True,Delayed Quote,USD,0.83333254,1.19 - 1.23,1.2,0.0,0.0,361,280,finmb_12827020,NasdaqCM,USD,6713939,2428228,1.0250001,5.540541,0.185 - 4.47,-3.2599998,-0.72930646,0.185,4.47,1559865600,1621249140,1628679540,1629115200,0.00999999,0.82644546,1630575073,1.22,-0.638,-0.2,-0.26,-4.6538463,-14400000,0.249,1.3308572,-0.12085712,-0.09081149,1.655,-0.44499993,4,"Jaguar Health, Inc.","Jaguar Health, Inc.",1.21,1630526403,0.00999999,1.2,1.23,1.19,2099627,PRE,NCM,us_market,-0.26888213,166157200,-6.05,4.859438,15,America/New_York,EDT,False,False,0,1.35,,,4.47,0.185,1.3309,1.655,6.71M,2.43M,137.32M,,136.09M,5.15%,11.50%,8.44M,1.38,6.15%,6.15%,8.06M,,,,,,0.00%,"Jun 06, 2019",,1:70,"Jun 06, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,-232.84%,-27.84%,-156.22%,9.76M,0.15,42.80%,6.11M,-20.99M,-42.24M,-0.6380,,32.25M,0.23,25.66M,80.46,3.50,0.25,-17.69M,-11.36M,Value,94104,Healthcare,34,"Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.",San Francisco,415 371 8300,CA,1609372800,United States,http://www.jaguar.health,86400,200 Pine Street,Biotechnology,Suite 400
t-2,JAGX,-22642000.0,137318000,1522000,,-7866000,,-7866000,5842000,1989000,-5375000,-5375000,,-581000,,,,0,2773000,8148000,784000,-2491000,,-7866000,-8271000,24759000.0,160238000.0,28428000.0,2117000.0,6556000.0,36234000.0,9000.0,-158130000.0,66000.0,1349000.0,25768000.0,6781000.0,686000.0,10723000.0,1508000.0,2660000.0,2219000.0,5456000.0,3150000.0,-1420000,-1625000,1253000,2259000,565000,-1666000,-2919000,621000,135000,-705000,2313000,3673000,-15045000.0,en-US,US,EQUITY,True,Delayed Quote,USD,0.83333254,1.19 - 1.23,1.2,0.0,0.0,361,280,finmb_12827020,NasdaqCM,USD,6713939,2428228,1.0250001,5.540541,0.185 - 4.47,-3.2599998,-0.72930646,0.185,4.47,1559865600,1621249140,1628679540,1629115200,0.00999999,0.82644546,1630575073,1.22,-0.638,-0.2,-0.26,-4.6538463,-14400000,0.249,1.3308572,-0.12085712,-0.09081149,1.655,-0.44499993,4,"Jaguar Health, Inc.","Jaguar Health, Inc.",1.21,1630526403,0.00999999,1.2,1.23,1.19,2099627,PRE,NCM,us_market,-0.26888213,166157200,-6.05,4.859438,15,America/New_York,EDT,False,False,0,1.35,,,4.47,0.185,1.3309,1.655,6.71M,2.43M,137.32M,,136.09M,5.15%,11.50%,8.44M,1.38,6.15%,6.15%,8.06M,,,,,,0.00%,"Jun 06, 2019",,1:70,"Jun 06, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,-232.84%,-27.84%,-156.22%,9.76M,0.15,42.80%,6.11M,-20.99M,-42.24M,-0.6380,,32.25M,0.23,25.66M,80.46,3.50,0.25,-17.69M,-11.36M,Value,94104,Healthcare,34,"Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.",San Francisco,415 371 8300,CA,1609372800,United States,http://www.jaguar.health,86400,200 Pine Street,Biotechnology,Suite 400
t-3,JAGX,-24553000.0,137318000,1405000,,-9238000,,-9238000,5486000,2136000,-4755000,-4755000,,-479000,,,,0,3167000,7922000,1031000,-4483000,,-9238000,-10597000,25181000.0,150885000.0,25158000.0,628000.0,5586000.0,37580000.0,7000.0,-150264000.0,96000.0,3015000.0,24758000.0,8960000.0,697000.0,11606000.0,2217000.0,400000.0,2354000.0,5240000.0,1926000.0,1233000,-689000,5414000,625000,4565000,1412000,-4002000,605000,350000,-2867000,1538000,4995000,-13152000.0,en-US,US,EQUITY,True,Delayed Quote,USD,0.83333254,1.19 - 1.23,1.2,0.0,0.0,361,280,finmb_12827020,NasdaqCM,USD,6713939,2428228,1.0250001,5.540541,0.185 - 4.47,-3.2599998,-0.72930646,0.185,4.47,1559865600,1621249140,1628679540,1629115200,0.00999999,0.82644546,1630575073,1.22,-0.638,-0.2,-0.26,-4.6538463,-14400000,0.249,1.3308572,-0.12085712,-0.09081149,1.655,-0.44499993,4,"Jaguar Health, Inc.","Jaguar Health, Inc.",1.21,1630526403,0.00999999,1.2,1.23,1.19,2099627,PRE,NCM,us_market,-0.26888213,166157200,-6.05,4.859438,15,America/New_York,EDT,False,False,0,1.35,,,4.47,0.185,1.3309,1.655,6.71M,2.43M,137.32M,,136.09M,5.15%,11.50%,8.44M,1.38,6.15%,6.15%,8.06M,,,,,,0.00%,"Jun 06, 2019",,1:70,"Jun 06, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,-232.84%,-27.84%,-156.22%,9.76M,0.15,42.80%,6.11M,-20.99M,-42.24M,-0.6380,,32.25M,0.23,25.66M,80.46,3.50,0.25,-17.69M,-11.36M,Value,94104,Healthcare,34,"Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.",San Francisco,415 371 8300,CA,1609372800,United States,http://www.jaguar.health,86400,200 Pine Street,Biotechnology,Suite 400
